| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20047210 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS44015624 | HTLV-1 | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS44043967 | HTLV-1 | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HTR1D |
|---|---|
| DrugBank ID | DB00248 |
| Drug Name | Cabergoline |
| Target ID | BE0000659 |
| UniProt ID | P28221 |
| Regulation Type | agonist |
| PubMed IDs | 18691132; 10641988 |
| Citations | Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.@@Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. |
| Groups | Approved |
| Direct Classification | Lysergic acids and derivatives |
| SMILES | [H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC |
| Pathways | |
| PharmGKB | PA448708 |
| ChEMBL | CHEMBL1201087 |
